

January 2, 2025

CHANGE IN PREFERRED DRUG LIST STATUS FOR BETA AGONIST DRUG CLASS, EFFECTIVE JANUARY 3, 2025

BACKGROUND

VDP is aware of the product discontinuation for brand name Xopenex inhalation solution in the Bronchodilators, Beta Agonist drug class, due to the shutdown of Akorn Pharmaceuticals.

KEY DETAILS

In response to the discontinuation of inhalation solution products with the preferred brand name Xopenex, VDP removed the non-preferred status from the generic Levalbuterol inhalation solution products on the preferred drug list (PDL) effective January 3, 2025.

Prescribers can prescribe the generic Levalbuterol inhalation solution without requiring a PDL prior authorization, allowing clients to continue accessing necessary medication.

The enclosed file lists the generic Levalbuterol products with their National Drug Codes.

ACTION

This change will appear in the daily formulary file as of January 3, 2025. MCOs must make the change by January 13, 2025.

RESOURCES

[2025 0103 - Levalbuterol NDC list.pdf](#)